Business
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weekssNDA filed in US, China and Japan; decisions expected H2 2026 Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of car
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x1Rza7IeLy1J5DmWciMF8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Ng--/https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252","width":300,"height":104},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/x1Rza7IeLy1J5DmWciMF8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Ng--/https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252","width":300,"height":104}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"sNDA filed in US, China and Japan; decisions expected H2 2026","length":61,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":276,"olType":false},{"type":"text","content":"Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.","length":415,"tagName":"p"},{"type":"text","content":"Results show that patients treated with Pluvicto experienced a higher frequency and depth of PSA response when combined with SoC (androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to SoC alone. Risk of PSA progression was 58% lower (HR 0.42; 95% CI: 0.30-0.59) in patients treated with Pluvicto plus SoC compared to SoC alone.","length":366,"tagName":"p"},{"type":"text","content":"“Our goal in hormone-sensitive prostate cancer is to attack and delay the cancer before it develops resistance,” said Fred Saad, Professor and Chairman, Department of Surg...